Heparin-induced Thrombocytopenia: Yet Another Treatment Paradox?

Summary

Few topics in medicine rival heparin-induced thrombocytopenia (HIT) for the unexpected twists and turns enough to rival the plot of many a mystery novel. The underlying theme- anticoagulant-induced thrombosis- seems improbable, but is well-established: despite thrombocytopenia, patients rarely bleed spontaneously or even exhibit petechiae (1); rather, thrombosis develops in 30-75% of patients with HIT, depending upon the clinical situation, and in proportions far greater than expected based on the original reason for receiving heparin (2-4).

But even beyond this fundamental contradiction, there exists for the unwary and uninformed practitioner several counterintuitive treatment paradoxes. One is the dichotomous nature of low-molecular-weight heparin (LMWH) respecting prevention and treatment of HIT. LMWH is far less likely to cause HIT than standard, unfractionated heparin (4, 5). Yet, for the patient with acute HIT caused by unfractionated heparin, LMWH is contraindicated (6, 7). The reason: LMWH preparations contain some heparin molecules with 12 or greater saccharide units, which are sufficiently long to bind platelet factor 4 (PF4), creating the multimolecular complexes bearing the HIT antigens. Consequently, ongoing platelet activation, thrombocytopenia, and thrombosis occur in many patients so treated (8).

• References

• 1 Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A. eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, Inc.; 2000: 43-80.
• 2 Lee DP, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A. eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, Inc.; 2000: 81-112.
• 3 Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
• 4 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
• 5 Funk S, Eichler P, Albrecht D, Ganzer D, Strobel U, Lubenow N, Greinacher A. Heparin-induced thrombocytopenia (HIT) in orthopedic patients – a prospective cohort trial comparing UFH and LMWH. Ann Hematol 2000; 79 (Suppl. 01) abstr. A92.
• 6 Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A. eds. Heparin-induced Thrombocytopenia. New York: Marcel Dekker, Inc.; 2000: 261-90.
• 7 Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 2001; 119 suppl 645-945.
• 8 Ranze O, Eichner A, Lubenow N, Kempf R, Greinacher A. The use of low-molecular-weight heparins in heparin-induced thrombocytopenia (HIT): a cohort study. Ann Hematol. 2000 79. suppl 1, abstr. P198.
• 9 Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12.
• 10 Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol 1999; 62: 44-8.
• 11 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
• 12 Contreras M. The appropriate use of platelets: an update from the Edinburgh Consensus Conference. Br J Haematol 1998; 101 (Suppl. 01) 10-2.
• 13 Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35.
• 14 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 950-7.
• 15 Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B. for the HIT Investigators Group.. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 1999; 99: 73-80.
• 16 Greinacher A, Janssens U, Berg G, Böck M, Kwasny H, Kemkes-Matthes B, Eichler P, Völpel H, Pötzsch B, Luz M. for the Heparin-associated Thrombocytopenia Study (HAT) Investigators.. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100: 587-93.
• 17 Chong BH. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A. eds. Heparin-Induced Thrombocytopenia. New York: Marcel Dekker, Inc.; 2000: 291-311.
• 18 Warkentin TE, Barkin RL. Newer strategies for the treatment of heparin-induced thrombocytopenia. Pharmacotherapy 1999; 19: 181-95.
• 19 De Valk HW, Banga JD, Wester JWJ, Brouwer CB, van Hessen MWJ, Meuwissen OJAT, Hart HC, Sixma JJ, Nieuwenhuis HK. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995; 123: 1-9.
• 20 Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61. [Erratum, Thromb Haemost 1993; 70: 1072.]
• 21 Anonymous.. Argatroban for treatment of heparin-induced thrombocytopenia. Med Lett Drugs Ther 2001; 43: 11-2.
• 22 Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, Dacosta A. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999; 82: 1199-200 (letter).
• 23 Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
• 24 Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets 1999; 10: 319-26.
• 25 Hughes M, Hayward CPM, Warkentin TE, Horsewood P, Chorneyko KA, Kelton JG. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188-94.
• 26 Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8.
• 27 Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-51.
• 28 Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y. Induction of monocyte tissue factor expression by antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia. Blood. 2001 in press (May 2001 issue).